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Abstract
BACKGROUND: Endometrial cancer is the most common cancer of the female genital tract. No effective biomarkers 
currently exist to allow for an efficient risk classification of endometrial carcinoma or to direct treatment (adjuvant 
radiation and/or chemotherapy) or to triage pelvic and para-aortic lymphadenectomy. L1 cell adhesion molecule 
(L1CAM) a transmembrane protein of the immunoglobulin family that has been implicated in promoting tumor 
cell proliferation, migration, invasion, and metastasis became an attractive candidate as a potential biomarker in 
endometrial carcinoma and potential therapeutic target in high-risk groups.
OBJECTIVES: Evaluation of L1CAM expression in endometrial carcinoma and correlation of this expression with 
various pathological parameters.
MATERIALS AND METHODS: Immunohistochemical staining for L1CAM was performed on paraffin-embedded 
sections of 80 cases of endometrial carcinomas that underwent total hysterectomy with bilateral salpingo-
oophorectomy. Expression of L1CAM in >10% of tumor cells was interpreted as positive.
RESULTS: L1CAM expression was detected in 22.5% of cases and showed statistically significant correlation with 
non-endometrioid histological type, high grade, high FIGO stage, high pathological (T) stage, cervical involvement, 
nodal metastasis, lymphovascular space invasion, and high-risk tumor according to the European Society for Medical 
Oncology system for risk stratification (p < 0.05).
CONCLUSION: The high rate of L1CAM expression in high-risk endometrial carcinomas suggests that L1CAM 
represents a potential marker for the identification of patients needing closer follow-up and aggressive treatment. In 
addition, its potential role as a therapeutic target for high-risk endometrial cancer seems promising.
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Introduction
Endometrial cancer is the most common 
cancer of the female genital tract and the fourth most 
commonly diagnosed cancer among women in the 
United States with 61,880 new cases and 12,160 
deaths estimated in 2019 [1].
In Egypt, endometrial carcinoma accounted for 
31.4% of all malignant female genital system tumors 
and 4% of all primary malignant tumors according to 
Pathology-based Cancer Registry, Ain-Shams Faculty 
of Medicine [2]. Endometrial carcinoma represented 
22.83% of all malignant female genital system tumors 
as reported by Cancer Pathology Registry, Cairo 
University, National Cancer Institute [3].
Although endometrial cancer is conventionally 
thought to be a cancer of the postmenopausal period, 
14% of cases are diagnosed in premenopausal women; 
5% of whom are younger than 40 years. The main 
risk factor of endometrial carcinoma is exposure to 
endogenous and exogenous estrogen associated with 
obesity, diabetes, early age at menarche, nulliparity, late-
onset menopause, old age, and use of tamoxifen [4].
Conventionally, endometrial carcinomas have 
been classified as type I and type II; type I tumors were 
estrogen dependent and associated with endometrial 
hyperplasia, whereas type II tumors were estrogen 
independent and associated with endometrial atrophy. 
Endometrial carcinoma is also classified according 
to histopathological characteristics, with the most 
common subtypes being endometrioid carcinoma, 
serous carcinoma, carcinosarcoma, and clear cell 
carcinoma [5].
Correlations have been noted between the 
subtypes in these two classification systems; type I 
cancers generally have endometrioid histology with 
good prognosis and most type II cancers are serous 
carcinomas with poor prognosis. The prognostic value 
of this dualistic classification remains limited because 
20% of endometrioid (i.e., type I) endometrial cancers 
relapse, whereas 50% of non-endometrioid (i.e., type II) 
endometrial cancers do not [6].
No effective biomarkers currently exist to 
allow for an efficient risk classification of endometrial 
carcinoma or to direct treatment (adjuvant radiation 
and/or chemotherapy) or to triage pelvic and para-
aortic lymphadenectomy [7].
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L1 cell adhesion molecule (L1CAM) – a 
transmembrane protein of the immunoglobulin family – 
has been implicated in promoting tumor cell proliferation, 
migration, invasion, and metastasis. L1CAM expression 
in tumor cells promotes disease progression by 
augmentation of cell motility, invasion, and metastasis 
in part through the activation of the extracellular 
signal-regulated kinase and also through epithelial-to-
mesenchymal transition and Wnt signaling [8].
L1CAM expression in endometrial carcinoma 
appears to be an independent predictor for poor 
survival, with overexpression in advanced stage and 
high-grade endometrial carcinoma, serous histology, 
positive peritoneal cytology, deep myometrial invasion, 
and positive pelvic and para-aortic lymph nodes. 
L1CAM became an attractive candidate as a potential 
biomarker in endometrial carcinoma and potential 
therapeutic target in high-risk groups [9].
Materials and Methods
Retrieval of cases
The material of this cross-sectional study 
was collected as 80 formalin-fixed, paraffin-embedded 
endometrial carcinoma tissue sections from archives of 
Pathology Department, Kasr AL-Ainy (Cairo University 
Hospital) in the period from March 2013 to September 
2016. The authors obtained the approval of Ethical 
Committee in the Faculty of Medicine, Cairo University.
Inclusion criteria included cases of endometrial 
carcinoma that underwent total hysterectomy with 
bilateral salpingo-oophorectomy. Exclusion criteria 
included cases received neoadjuvant therapy or cases 
with missed data.
The data collected from the pathology reports 
of these cases included age at time of diagnosis and 
lymph node status; nodal status was only documented 
for cases where pelvic lymphadenectomy was 
performed.
Histopathological examination
Each paraffin block was cut by rotatory 
microtome at 4 μm thickness then mounted on glass 
slides and stained by hematoxylin and eosin for routine 
histopathological examination and on charged slides 
for immunostaining.
The tumors were histologically classified 
according to the latest World Health Organization 
recommendations [10]. Histological grading was 
performed according to the FIGO grading system [11]. 
Pathological staging was accomplished according to 
the FIGO staging system [12] and the eighth edition 
(2017) of the American Joint Committee on Cancer’s 
AJCC Cancer Staging Manual [13].
Lymphovascular space invasion (LVSI) was 
defined as the presence of tumor cells in a space lined 
by endothelial cells outside the immediate invasive 
border; intratumoral LVSI foci were not considered. 
Risk stratification was performed according to modified 
European Society for Medical Oncology (ESMO) 
system [14].
L1CAM immunohistochemical staining and 
evaluation
Immunostaining was done using fully 
automated immunohistochemical system, BenchMark 
XT (Ventana) autostainer, pH 6 for mouse monoclonal 
antibody L1CAM Ab-1, clone UJ127, Cat. #MS-770-R7, 
and 7.0 ml obtained from Thermo Fisher Scientific 
Anatomical Pathology (Fremont, CA, USA).
A section of schwannoma was used as positive 
control according to the manufacturer recommendations. 
Furthermore, nerves running through the deeper 
myometrium served as internal positive controls.
L1CAM membranous expression level was 
classified into two categories depending on the 
percentage of cells stained. Cases with more than 10% 
positively stained tumor cells were considered positive 
and those with <10% positively stained tumor cell were 
considered negative [15].
Statistical analysis
The histopathological and 
immunohistochemical data were then transferred to the 
SPSS software program, version 25 to be statistically 
analyzed. Simple descriptive statistics (arithmetic 
mean and standard deviation) were used for summary 
of quantitative data and frequencies were used for 
qualitative data. Estimation of the association between 
categorical variables was performed using the Chi-square 
test. p < 0.05 is considered as statistically significant.
Results
This study included 80 cases of endometrial 
carcinoma. The age of them ranged from 38 to 77 years 
with a mean of 60 ± 8.75 years. Among the studied cases, 
83.8% of the cases were endometrioid carcinoma while 
6.3% were serous carcinoma and 10% were malignant 
mixed Müllerian tumor (MMMT). Concerning FIGO 
grade, 20% of the cases were Grade 1, 45% were 
Grade 2, and 35% were Grade 3. Regarding FIGO 
stage, 68.8% of the cases were classified as FIGO 
Stage I, 13.8% were FIGO Stage II, and 17.5% were 
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FIGO Stage III. Out of all cases, 71.25% were classified 
as T1, 15% were T2, and 13.75% were T3.
Less than half of myometrial invasion was 
documented in 57.5% of the cases. Cervical, serosal, 
and/or adnexal and parametrial involvement by the 
tumor were detected in 17.5%, 11.25%, and 11.25% 
of the cases, respectively. Nodal metastasis and LVSI 
were present in 6.25% and 26.25% of the cases, 
respectively. According to ESMO system of endometrial 
carcinoma risk stratification, 43.75% of the cases were 
considered as high risk. The pathological characteristics 
of the studied cases are summarized in Table 1.
and LVSI (p = 0.046). There were direct correlations 
between L1CAM expression and extent of myometrial 
invasion, serosal and/or adnexal involvement, and 
parametrial involvement. However, there were no 
significant differences in any of these correlations. 
Concerning ESMO risk stratification system, cases 
considered as high risk showed the highest rate 
of L1CAM expression with statistically significant 
difference (p = 0.000). Correlation of L1CAM expression 
with various pathological characteristics among studied 
cases is summarized in Table 2.
Discussion
Endometrial cancer is the most common 
gynecological malignancy. Currently available 
clinical and histopathological data do not allow for an 
efficient and well reproducible risk classification. This 
is especially true for early-stage disease where few 
patients suffer fatal relapse in spite of the absence of 
the established high-risk criteria [7].
L1CAM, a transmembrane protein of the 
immunoglobulin family that implicated in promoting 
tumor cell proliferation, migration, invasion, and 
metastasis, has been investigated in endometrial 
carcinoma. L1CAM immunohistochemistry could 
be an additional tool of considerable value for risk 
stratification in endometrial carcinomas, particularly 
recurrence potential and pelvic lymph node 
involvement [16].
L1CAM expression in this study was positive 
in 22.5% of cases. This figure was close to studies 
reported by van der Putten et al., 2018; Kommoss et al., 
Table 1: Pathological characteristics of the studied cases
Pathological characteristics n (%)
Histopathological type
Endometrioid carcinoma 67 (83.75)
Serous carcinoma 5 (6.25)
MMMT 8 (10)
Histopathological grade
Grade 1 16 (20)
Grade 2 36 (45)
Grade 3 28 (35)
FIGO stage
I 55 (68.75)
II 11 (13.75)
III 14 (17.5)
Tumor (T) pathological stage
T1 57 (71.25)
T2 12 (15)
T3 11 (13.75)
Myometrial invasion
Less than half 46 (57.5)
More than half 34 (42.5)
Cervical involvement
Present 14 (17.5)
Absent 66 (82.5)
Serosal and/or adnexal involvement
Present 9 (11.25)
Absent 71 (88.75)
Parametrial involvement
Present 6 (7.5)
Absent 74 (92.5)
Lymph nodal metastasis
Present 5 (6.25)
Absent 16 (20)
Could not be assessed 59 (73.75)
LVSI
Present 21 (26.25)
Absent 59 (73.75)
ESMO system of endometrial carcinoma risk stratification
Low 27 (33.75)
Intermediate 10 (12.5)
Intermediate-high 8 (10)
High 35 (43.75)
MMMT: Malignant mixed Müllerian tumor, LVSI: Lymphovascular space invasion, ESMO: European Society 
for Medical Oncology.
L1CAM showed positive membranous 
expression in 22.5% of the cases while 77.5% of the 
cases were negative for it. Serous carcinoma cases 
showed the highest rate of L1CAM expression followed 
by MMMT then endometrioid histology with statistically 
significant difference (p = 0.000), Figure 1.
Grade 3 cases showed the highest rate 
of L1CAM expression followed by Grade 2 and 
then Grade 1 with statistically significant difference 
(p = 0.002). There were statistically significant direct 
correlations between L1CAM expression and both 
FIGO stage (p = 0.006) and tumor (T) pathological 
stage (p = 0.017).
Statistically significant direct correlations were 
found between positive L1CAM expression and cervical 
involvement (p = 0.007), nodal metastasis (p = 0.027), 
Figure 1: Positive L1CAM expression in various histological subtypes 
of endometrial carcinoma among the studied cases (a) endometrioid 
carcinoma (×100 original magnification), (b) endometrioid carcinoma 
(×400 original magnification), (c) serous carcinoma (×100 original 
magnification), (d) serous carcinoma (×400 original magnification), 
(e) malignant mixed Müllerian tumor (×100 original magnification), 
(f) malignant mixed Müllerian tumor (×400 original magnification)
a b c
d e f
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2018; Pasanen et al., 2017; van der Putten et al., 2016; 
and Geels et al., 2016, where L1CAM positivity was 
found in 18%, 21.5%, 26.6%, 17%, and 17% of cases, 
respectively [17], [18], [19], [20], [21].
On the contrary, a lower rate of positive 
expression (8.4%) was reported by Kommoss et al., 
2017, and a higher rate of positivity expression (51%) 
was reported by Van Gool et al., 2016 [7], [8]. It is 
worthy to mention that the former concerned with low 
risk cases and the later concerned with high-risk 
cases.
Regarding the histological subtypes, serous 
carcinoma showed the highest rate of L1CAM 
expression followed by MMMT and finally endometrioid 
carcinoma with statistically significant difference. This 
was compatible with results of Kommoss et al., 2018; 
Geels et al., 2016; and Bosse et al., 2014, who reported 
higher rate of L1CAM expression in non-endometrioid 
types, particularly serous carcinoma as reported by 
Tangen et al., 2017 [18], [21], [22], [23].
In this study, the rate of L1CAM expression 
increased with the increase in the histological grade; 
Grade 1 (0%), Grade 2 (16.7%), and Grade 3 (42.9%) 
with statistically significant difference. This was 
compatible with the results of Kommoss et al., 2018, 
yet, with quite higher rates; 15.5%, 17.5%, and 67%, 
respectively [18]. Similarly, Van Gool et al., 2016, 
reported significant association between L1CAM 
expression and higher tumor grade [8].
Concerning FIGO stage, the rate of L1CAM 
positivity increased with the increase in the FIGO stage; 
I (12.7%), II (36.4.7%), and III (50%) with statistically 
significant difference. This agreed with most of reported 
studies where L1CAM expression was correlated with 
higher FIGO stages [9], [18], [20]. Dissimilarly, no 
significant difference was reported by Van Gool et al., 
2016 [8].
Regarding (T) pathological staging, cases 
classified as T3 showed the highest rate of L1CAM 
expression (45.5%) followed by those classified as T2 
(41.7%) and finally T1 cases (14%) with statistically 
significant difference. This correlation was not evaluated 
by other comparative studies. However, it is worthy 
to mention that the definitions of the T categories of 
endometrial carcinoma correspond to the stages 
accepted by FIGO.
Concerning the extent of myometrial 
invasion, cases showed more than half of 
myometrial invasion showed higher rate of L1CAM 
positivity, but these results were statistically 
insignificant similar to a study performed by Geels 
et al., 2016 [21]. The same findings yet with 
statistically significant difference were reported by 
many studies [20], [23], [24].
Cases with cervical involvement by the tumor 
showed higher rate of L1CAM expression than cases 
with free cervix with statistically significant difference. 
This agreed with the results of Weinberger et al., 
2019 [25].
In this study, cases with serosal/adnexal and 
parametrial involvement by the tumor showed higher 
rates of L1CAM expression. However, no statistically 
significant difference could be documented. These 
correlations were not evaluated by other comparative 
studies.
In this study, cases with positive nodal 
metastasis showed higher rate of L1CAM positivity with 
statistically significant difference. Similar findings were 
reported by Weinberger et al., 2019, and Tangen et al., 
2017 [23], [25].
On the contrary, Geels et al., 2016, reported 
discordant results as they included only one case 
with positive nodal metastasis, in which the tumor 
was L1CAM negative. In addition, their result was 
statistically insignificant [21].
L1CAM expression rate in this study was 
higher in cases showed LVSI than in those with 
absent LVSI with statistically significant difference. 
This was consistent with the results of most reported 
studies [21], [25].
Concerning ESMO risk stratification system, 
high-risk cases in this study showed the highest rate 
of L1CAM expression with statistically significant 
difference. Similar results were reported by Kommoss 
et al., 2018 [18].
Table 2: Correlation of L1CAM expression with various 
pathological characteristics among the studied cases
Pathological characteristics L1CAM positive L1CAM negative p value
Histopathological type
Endometrioid carcinoma 9 (13.4) 58 (86.6) 0.000*
Serous carcinoma 4 (80) 1 (20)
MMMT 5 (62.5) 3 (37.5)
Histopathological grade
Grade 1 0 (0) 16 (100) 0.002*
Grade 2 6 (16.7) 30 (83.3)
Grade 3 12 (42.9) 16 (57.1)
FIGO stage
I 7 (12.7) 48 (87.3) 0.006*
II 4 (36.4) 7 (63.6)
III 7 (50) 7 (50)
Tumor (T) pathological stage
T1 8 (14) 49 (86) 0.017*
T2 5 (41.7) 7 (58.3)
T3 5 (45.5) 6 (54.5)
Myometrial invasion
Less than half 10 (21.7) 36 (78.3) 0.850
More than half 8 (23.5) 26 (76.5)
Cervical involvement
Present 7 (50) 7 (50) 0.007*
Absent 11 (16.7) 55 (83.3)
Serosal and/or adnexal involvement
Present 3 (33.3) 6 (66.7) 0.409
Absent 15 (21.1) 56 (78.9)
Parametrial involvement
Present 3 (50) 3 (50) 0.093
Absent 15 (20.3) 59 (79.7)
Lymph nodal metastasis
Present 4 (80) 1 (20) 0.027*
Absent 4 (25) 12 (75)
LVSI
Present 8 (38.1) 13 (61.9) 0.046*
Absent 10 (16.9) 49 (83.1)
ESMO system of endometrial carcinoma risk stratification
Low 1 (3.7) 26 (96.3) 0.000*
Intermediate 0 (0) 10 (100)
Intermediate-high 1 (12.5) 7 (87.5)
High 16 (45.7) 19 (54.3)
*Statistically significant. ESMO: European Society for Medical Oncology, MMMT: Malignant mixed 
Müllerian tumor.
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Conclusion
Our study documented that L1CAM expression 
was significantly correlated with non-endometrioid 
histology, high FIGO grade, high FIGO stage, high (T) 
stage, cervical involvement, LVSI, and high-risk tumor 
according to modified ESMO system.
These findings were consistent with most 
of reported studies making L1CAM a possible useful 
biomarker in identification of endometrial cancers 
with aggressive behavior for better risk classification, 
identification of patients needing closer follow-up, and 
management direction. In addition, its potential role as 
a therapeutic target for high-risk endometrial cancer 
seems promising.
Furthermore, significant correlation between 
L1CAM expression and positive nodal metastasis 
suggests the possible role of this marker as a predictor 
of lymph node metastasis helping to improve selection 
of patients requiring lymphadenectomy.
Further studies with larger samples, comparing 
L1CAM expression in pre-operative and post-operative 
biopsies, correlation of L1CAM expression with the 
molecular classification of Tumor Cancer Genome 
Atlas, and long-term follow-up are required to establish 
the prognostic significance of L1CAM expression in 
endometrial carcinoma, particularly occurrence of 
recurrence and survival. Prospective trials are needed 
to evaluate the clinical significance of L1CAM for 
risk assessment and to guide potential alterations of 
surgical and adjuvant treatment strategies.
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